期刊文献+

VEGF siRNA抑制人胰腺癌PANC-1细胞体外生长的研究 被引量:3

Suppression of VEGF siRNA on Growth of Human Pancreatic Cancer Cells in Vitro
原文传递
导出
摘要 目的了解载体携带的小干扰RNA(small interfering RNA,siRNA)对人胰腺癌细胞株PANC-1血管内皮生长因子(vascular endothelial growth factor,VEGF)表达的抑制作用以及对肿瘤细胞生长的影响。方法设计并合成2对针对VEGF的siRNA真核表达载体(PU-VEGF-siRNA1组和PU-VEGF-siRNA2组,简称为重组质粒组),经脂质体Lipofectamine 2000转染PANC-1细胞,经G418筛选后获得稳定转染细胞株,空载体转染组作为实验对照组,未转染组作为空白对照组。采用MTT法检测转染后PANC-1细胞的增殖,流式细胞仪检测转染后PANC-1细胞的凋亡率和细胞周期,逆转录聚合酶链反应(RT-PCR)检测转染后VEGF mRNA表达情况。结果与实验对照组和空白对照组比较,两重组质粒组PANC-1细胞的增殖减慢,细胞凋亡率增加,VEGF mRNA表达明显下降,差异均有统计学意义(P<0.05);细胞周期结果显示,两重组质粒组S期细胞所占比例较两对照组明显减少(P<0.05)。结论 siRNA能有效抑制胰腺癌细胞VEGF的表达,并能在体外抑制人胰腺癌细胞株PANC-1细胞的生长。
出处 《中国普外基础与临床杂志》 CAS 2011年第6期651-654,共4页 Chinese Journal of Bases and Clinics In General Surgery
  • 相关文献

参考文献9

二级参考文献44

  • 1Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey Ⅰ and Gyula Ostoros, et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non- small cell lung cancer. Clin Cancer Res 2005, 11: 7344 -7353.
  • 2Al-Rawi MA, Mansel RE and Jiang WG. Lymphangiogenesis and its role in cancer. Histol Histopathol 2005, 20: 283-298.
  • 3Inoue A, Moriya H, Katada N, Tanabe S, Kobayashi N, Watanabe M and Okayasu I, et al. Intratumoral lymphangiogenesis of esophageal squamous cell carcinoma and relationship with regulatory factors and prognosis. Pathol Int 2008, 58:611- 619.
  • 4Jackson DG. New molecular markers for the study of tumor lymphangiogenesis. Anticancer Res 2001, 21: 4279-4283.
  • 5Da MX, Wu Z and Tian HW. Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res 2008, 39:365- 372.
  • 6Cao Y and Zhong W. Tumor-derived lymphangiogenic factors and lymphatic metastasis. Biomed Pharmacother 2007, 61:534 -539.
  • 7SU JL, Chen PS, Chien MH, Chen PB, Chen YH, Lai CC and Hung MC, et al. Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer Cell 2008, 13: 557- 560.
  • 8Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998, 12:1063- 1073.
  • 9Williams CS, Mann M and DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18: 7908 -7916.
  • 10Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Matzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004, 215:1 -20.

共引文献53

同被引文献41

  • 1张丽萍,聂青,康静波,李建国,齐文杰.伽玛刀治疗晚期胰腺癌的临床研究[J].中国现代医学杂志,2005,15(5):723-725. 被引量:12
  • 2张太平,赵玉沛.胰腺癌基因治疗的现状与展望[J].中华肝胆外科杂志,2007,13(3):148-151. 被引量:7
  • 3Tuschl T. Expanding small RNA interference [ J ]. NAT Biotechnol, 2002,20:446-448.
  • 4Yigitbasi OG, Younes MN, Doan D,et al. Tumor Cell and Endothe- lial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade[ J]. Cancer Res ,2004,64 (21) :7977-7984.
  • 5Suzuki K, Hagashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma [ J ]. Cancer Res, 1996, 56 ( 13 ) : 3004-3009.
  • 6McManus MT,Sharp PA. Gene silencing in mammals by small in- terfering RNAs[J] ,Nat Rev Genet,2002,3(10) :737-747.
  • 7Marconcini L, Marchio S, Morbidelli L, et al. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro [ J] I. Proc Natl cad Sci USA, 1999,96 (17) :9671-9676.
  • 8Yang L,Lin C,Jin C,et al.lncRNA dependent mechanisms of androgen receptor regulated gene activation programs.Nature,2013,500(7464): 598-602.
  • 9Shi X,Sun M,Liu H,et al.Long non-coding RNAs: a new frontier in the study of human diseases.Cancer Lett,2013,339(2): 159-166..
  • 10Jiang Y,Li Y,Fang S,et al.The role of MALAT1 correlates with HPV in cervical cancer.Oncol Lett,2014,7(6): 2135-2141.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部